Chengcheng Shi

411 citations
22 papers · 261 indexed · h-index 8
Topics
Cerebrovascular and Carotid Artery Diseases (4 papers)Acute Ischemic Stroke Management (4 papers)Ubiquitin and proteasome pathways (4 papers)

In The Last Decade

Chengcheng Shi

19 papers receiving 260 citations

Peers

Chengcheng Shi
Comparison fields: 5 of 54
  • Molecular Biology 168
  • Oncology 93
  • Pulmonary and Respiratory Medicine 75
  • Cancer Research 56
  • Epidemiology 24
Replace Marco Basiricò with:
Marco Basiricò Italy
Jindan An China
Chengkai Jiang China
Xiangbin Wan China
Moubin Lin China
Koji Fukase Japan
Yun‐Kai Lin China
Ruonan Shao China
Daniel L. Spitz United States
Fenggang Hou China
Chengcheng Shi relative to Marco Basiricò Italy Marco Basiricò's profile →
Citations per field
00.5×1.5×1.9×
Marco Basiricò · 1×
Citations per year

Countries citing papers authored by Chengcheng Shi

Since Specialization
Citations

This map shows the geographic impact of Chengcheng Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengcheng Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengcheng Shi more than expected).

Fields of papers citing papers by Chengcheng Shi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengcheng Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengcheng Shi. The network helps show where Chengcheng Shi may publish in the future.

Co-authorship network of co-authors of Chengcheng Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Chengcheng Shi. A scholar is included among the top collaborators of Chengcheng Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengcheng Shi. Chengcheng Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 1
2 0
3 0
4 1
5 0
6 2
7 6
8 21
9 3
10 6
11 5
12 76
13 2
14 2
15 8
16 40
17 11
18 46
19 14
20
244-MPT over comes gefitinib resistance in non-small cell lung cancer cells
1

About Chengcheng Shi

Chengcheng Shi is a scholar working on Transplantation, Pulmonary and Respiratory Medicine and Oncology, having authored 22 papers that have together received 261 indexed citations. Recurring topics across this work include Cerebrovascular and Carotid Artery Diseases (4 papers), Acute Ischemic Stroke Management (4 papers) and Ubiquitin and proteasome pathways (4 papers). The work is most often cited by research in Cancer Research (56 citations), Oncology (93 citations) and Molecular Biology (168 citations). Chengcheng Shi has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Huapeng Zhang, Yi Zhang, Xinwei Han, Xueliang Zhou, Zhenqiang Sun, Zaoqu Liu, Dechao Jiao, Yuyuan Zhang, Shanshan Li and Shuijun Zhang. Their work appears in journals such as Environmental Science & Technology, Scientific Reports and The FASEB Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026